Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice

A diabetogenic alloxan regimen produced lesions in all stomachs of treated animals, either rats (200 mg.kg(-1) s.c.) or mice (400 mg.kg(-1) i.p.). In control animals, the lesions, when developed (i.e. 24 h following applicati on), appear to be quite sustained, and consistently present also after 1 or 2 weeks. The application of the pentadecapeptide BPC 157 (10 mu g or 10 ng .kg(-1) i.p. coadministered together with alloxan) would significantly atte nuate these lesions' appearance. This beneficial effect seems to be present in either rats or mice and in either of the tested intervals. Importantly, the beneficial effect seems to be shared by both microgram and nanogram re gimens. (C) 1999 Elsevier Science Ltd. Published by Editions scientifiques et medicales Elsevier SAS.